IRVINE, Calif., Sept. 20, 2005 (PRIMEZONE) -- "In yet another in what has been a whirlwind of recently reported breakthrough developments, Stemcells Inc. is reporting that researchers in conjunction with the Reeve Irvine Research Center at the University of California, Irvine have restored lost motor function to a mouse with spinal cord injuries using the companies proprietary human stem cells," stated SmallCap Sentinel analyst D.R. Clark. "Mice who had experienced loss of hind leg mobility as a result of crush injuries were able to walk again after the transplant of human neural stem cells, effectively reversing the paralysis according to the study."
Support for the study was also provided by the Christopher Reeve Foundation through its International Research Consortium on Spinal Cord Injury.
"Breakthroughs are coming fast and furious in the stem cell arena, garnering headlines on front pages and financial pages," said Clark. "It's like a benevolent game of one upmanship, with spectacular reports trumping previously triumphant news. Let's hope that it continues as such and that soon, humans will directly benefit from the fruits of the researchers' labor."
An informational report titled "Looking at the Political Impact on Stem Cell Research" has been made available free of charge via financial courier StockUpTicks.com at www.SmallCapSentinel.com
New Life Scientific (OTCBB:NWLF), which endeavors to blend Eastern European research & development with Western management, Stemcells Inc. (Nasdaq:STEM), Aastrom Biosciences Inc. (Nasdaq:ASTM), and Geron Corp. (Nasdaq:GERN) will be discussed in the report.
Individuals may also register to receive free future reports at: http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect the results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project its capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid thirty-six hundred dollars for preparation and distribution of this report and other advertising services by Emerging Markets Consulting LLC. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.